MELBOURN, England, July 15, 2015 /PRNewswire/ --
Aegate, the leader in medicine verification and authentication services, is pleased to announce an important milestone has been reached in Cyprus with live scanning of medicines at point of dispense - enabling the ability to ensure patient safety against counterfeit and expired medicines.
(Logo: http://photos.prnewswire.com/prnh/20150610/748687 )
Pharmacies throughout Cyprus now have the ability to be Aegate Safe, putting patient safety first and expanding the opportunity to provide a deeper level of patient care.
The Aegate model has been successfully tested by over 20,000 pharmacy dispensing points in the last eight years in several European countries. The positive overall impact for both the pharmacy and the service provider has been increased patient safety by stopping 1.8 million medicines which should not have been dispensed.
The introduction of the Falsified Medicines Directive requires medicines to be uniquely serialised, protected by tamper-proof seals and their authenticity verified before being dispensed to patients. Every pharmacy in the EU will be obligated to have the ability to scan the serialised codes - Cyprus is Aegate Ready.
Mark De Simone, Aegate CEO commented: "We are very proud to have another European Country go live with the Aegate service, ready to protect patients from falsified, expired or recalled medicines: Patient Safety cannot wait!"
About Aegate
With a documented history of some 3.3 billion medicines scanned to date with an average rate of 200,000 transactions per hour across 20,000 dispensing points, Aegate is the principal active market leader in medicines verification. Aegate's Reach, Assure and Protect services meets the needs of all stakeholders. Supported internationally by manufacturers and pharmacists alike, Aegate is a European company with offices throughout Europe. Our mission is to protect patients from falsified, recalled or expired medicines.
We operate a highly secure real‐time system to verify the authenticity of medicines. This operates seamlessly from manufacturer to pharmacy, and fully meets the requirements of European legislation for falsified medicines. The Aegate network also supports messaging services that provide additional information for the pharmacist at the point of dispense, such as regulatory or drug safety advice and patient education or adherence information.
For more information on Aegate, please visit http://www.aegate.com
Media contact information: Miriam Foster
Head of Marketing & Communications
marketing@aegate.com
T: +44(0)1763-268-160
Share this article